ArticleVaccines2021

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer.

Rodney P Rocconi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.